Linus Biotechnology, a spinoff of New York City-based Mount Sinai Innovation Partners and a precision exposome medicine company, is slated to develop a tech platform with exposome sequencing.
Five things to know:
- Mount Sinai Innovation Partners and Linus Biotechnology inked an exclusive worldwide licensing agreement with the Icahn School of Medicine at Mount Sinai, according to a Nov. 17 news release.
- LinusBio expects to develop a technology platform that will build on breakthroughs in exposome sequencing by researchers from Mount Sinai's Department of Environmental Medicine and Public Health.
- The spinoff's program pipeline consists of precision exposome medicine biomarkers and targets discovery across diseases where there are no molecular endpoints available in clinical trials. These diseases include autism spectrum disorder, inflammatory bowel disease, renal disease; the project is expected to apply to oncology as well. The company plans to launch StrandDX-ASD, a molecular biomarker for autism that can be applied at birth, subject to regulatory approval.
- "LinusBio's commercial sequencing laboratory will accelerate bringing applications to patient populations with huge unmet needs," said Manish Arora, PhD, vice chair of the Department of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai and co-founder of LinusBio.
- "We look forward to working with LinusBio, as it aims to become a leader in precision exposome medicine and drives forward our mission to bring Mount Sinai's innovative, patient-first discoveries to society," said Erik Lium, PhD, president of Mount Sinai Innovation Partners and executive vice president and chief commercial innovation officer of Mount Sinai Health System.